Satavaptan

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Satavaptan
(IUPAC) ime
N-(tert-butyl)-4[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl3-methoxybenzamide
Klinički podaci
Identifikatori
CAS broj 185913-78-4
ATC kod nije dodeljen
PubChem[1][2] 9810773
Hemijski podaci
Formula C33H45N3O8S 
Mol. masa 643.789
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Satavaptan (INN; SR121463, Aquilda) je antagonist vazopresin-2 receptora[3] koji se ispituje za potencijalnu primenu u lečenju hiponatremije. On se takođe ispituje za premenu u tretmanima ascita.[4] Ovaj lek je razvila kompanija Sanofi-Aventis.

Literatura[uredi | uredi kod]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Soupart A, Gross P, Legros JJ, et al. (November 2006). „Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist”. Clin J Am Soc Nephrol 1 (6): 1154–60. DOI:10.2215/CJN.00160106. PMID 17699341. 
  4. Ginès P, Wong F, Watson H, Milutinovic S, Ruiz Del Arbol L, Olteanu D (February 2008). „Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial”. Hepatology 48 (1): 204–13. DOI:10.1002/hep.22293. PMID 18508290. 

Spoljašnje veze[uredi | uredi kod]

Šablon:Diuretici Šablon:Neuropeptidni ligandi